A new FDA strategy aims to get medicines to the market faster

The FDA has launched a pilot program with Eli Lilly and Regeneron to accelerate the development and approval of U.S. drug manufacturing facilities by engaging companies during design and construction phases. The initiative aims to reduce delays, improve compliance, and strengthen the domestic pharmaceutical supply chain to reduce reliance on overseas production.